IMNN Key Statistics, Chart & Performance
The current stock price of IMNN is 3.9 USD. In the past month the price decreased by -1.52%. In the past year, price decreased by -64.49%.
IMNN Latest News, Press Relases and Analysis
IMNN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.92 | 399.57B | ||
| AMGN | AMGEN INC | 15.08 | 177.64B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.40B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.24 | 115.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.96 | 75.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 898.27 | 60.52B | ||
| INSM | INSMED INC | N/A | 43.51B | ||
| NTRA | NATERA INC | N/A | 33.75B | ||
| BIIB | BIOGEN INC | 10.83 | 26.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.54 | 21.07B | ||
| INCY | INCYTE CORP | 15.97 | 20.13B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About IMNN
Company Profile
Imunon, Inc. is a clinical stage oncology drug company. The company is headquartered in Lawrenceville, New Jersey and currently employs 25 full-time employees. The firm is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The firm is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Company Info
IMUNON INC
997 Lenox Dr Ste 100
Lawrenceville NEW JERSEY US
Employees: 25
Phone: 16098969100
IMUNON INC / IMNN FAQ
Can you describe the business of IMUNON INC?
Imunon, Inc. is a clinical stage oncology drug company. The company is headquartered in Lawrenceville, New Jersey and currently employs 25 full-time employees. The firm is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The firm is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
What is the stock price of IMUNON INC today?
The current stock price of IMNN is 3.9 USD. The price decreased by -2.5% in the last trading session.
Does IMUNON INC pay dividends?
IMNN does not pay a dividend.
How is the ChartMill rating for IMUNON INC?
IMNN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for IMNN stock?
10 analysts have analysed IMNN and the average price target is 84.53 USD. This implies a price increase of 2067.36% is expected in the next year compared to the current price of 3.9.
What is the outstanding short interest for IMUNON INC?
The outstanding short interest for IMUNON INC (IMNN) is 6.59% of its float.
IMNN Technical Analysis
IMNN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IMNN. The financial health of IMNN is average, but there are quite some concerns on its profitability.
IMNN Financial Highlights
Over the last trailing twelve months IMNN reported a non-GAAP Earnings per Share(EPS) of -11.25. The EPS increased by 7.26% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -179.17% | ||
| ROE | -591.97% | ||
| Debt/Equity | 0 |
IMNN Forecast & Estimates
10 analysts have analysed IMNN and the average price target is 84.53 USD. This implies a price increase of 2067.36% is expected in the next year compared to the current price of 3.9.